NEW YORK (GenomeWeb) — Inivata announced today it has received a draft Medicare local coverage determination (LCD) through MolDx for its blood-based InVisionFirst-Lung test, a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.

In the draft LCD, Medicare administrative contractor Palmetto GBA has recommended coverage for InVisionFirst-Lung, Inivata said. The draft will go through a public comment period before being finalized and implemented.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.